Indefinite Delivery Contract HHSN261201200025I

The National Center for Advancing Translational Sciences (NCATS), a civilian agency, has awarded an indefinite delivery contract (IDC) worth up to $48,622,546 to Charles River Laboratories, Inc. to provide safety evaluation and toxicology studies and related services to support drug development. The contract has a period of performance from August 2024 to August 2030. Under this IDC, Charles River will perform in vitro and in vivo exploratory and Investigational New Drug (IND)-directed...

The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, has awarded a $48.6 million multiple-award indefinite delivery contract to conduct safety evaluation and toxicology studies in support of drug development. The contract has a 6-year ordering period and allows NCATS to issue task orders for in vitro and in vivo safety testing services, including genetic toxicology, general toxicology, and pharmacology...

This is a multiple award indefinite delivery contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to conduct safety evaluation and toxicology studies to support drug development. The $48.6 million contract has a 6-year ordering period from June 2024 to June 2030. The contractor, IIT Research Institute (IITRI), a non-profit research organization, will perform in vitro and in vivo exploratory and...

This indefinite delivery contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $48.6 million multiple-award IDC has a 6-year ordering period from June 2024 to June 2030. The contract aims to procure safety evaluation and toxicology studies and related services to support drug development efforts at NCATS....

The National Institutes of Health National Institute of Neurological Disorders and Stroke awarded an indefinite-delivery/indefinite-quantity contract to the University of Illinois with a potential value of $174.47 million. The contract supports the Pharmacology and Toxicology for Therapeutics Program, which aims to advance promising new treatments through preclinical testing. Under the contract, the University of Illinois will provide management and operations support services, as well as...

The federal contract IDV award is for safety evaluation and toxicology studies and related services to support drug development efforts of the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The prime contractor, SRI International, a nonprofit research and development institute, will provide in vitro and in vivo exploratory and Investigational New Drug (IND)-directed toxicology studies for small molecule and biologic...

The Department of Health and Human Services Food and Drug Administration awarded a single award indefinite delivery contract to the American College of Medical Toxicology, Inc. The IDC has a potential value of $16M and a period of performance through September 2029. Two task orders have been issued against the vehicle to date. The first task order is for $565K and focuses on near real-time surveillance of stimulants related to the overdose crisis through expansion of ACMT's Drug Overdose...

Altasciences Clinical Kansas Inc. was awarded a single-award indefinite delivery contract from the Department of Health and Human Services Food and Drug Administration valued at up to $5 million. The contract aims to advance generic drug approvals through the conduct of bioequivalence studies and characterization of generic drugs. Three firm fixed price delivery orders have been issued against this contract to date, with places of performance in Overland Park, Kansas. The first delivery order,...

This Indefinite Delivery Contract is a parent IDIQ vehicle awarded by the National Institutes of Health's National Institute of Neurological Disorders and Stroke to Southern Research Institute, a non-profit research organization. The Pharmacology and Toxicology for Therapeutics Program (PTTP) IDIQ has a total potential value of $174,470,000 and a period of performance through September 12, 2026. Under this IDIQ, Southern Research has been awarded multiple task orders to provide drug discovery,...

This indefinite delivery contract (IDC) was awarded by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services, to Sri International, a non-profit research and development institute. The $9.75 million IDC has a period of performance from September 12, 2023 to September 11, 2028 and is for toxicological evaluations of potential medications to support NIDA's mission. Under this IDC, Sri International has been awarded two task orders so far....